Patents by Inventor Dan BEDNARIK

Dan BEDNARIK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230399613
    Abstract: The present invention provides an isolated cell composition suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s). In various embodiments, the composition is predominately CD8+ T cells, and at least about 20% of T cells in the composition exhibit a central or effector memory phenotype, providing for a robust and durable adoptive therapy from a natural T cell repertoire that has undergone natural selection.
    Type: Application
    Filed: November 18, 2022
    Publication date: December 14, 2023
    Inventors: Mathias OELKE, Kristi JONES, Sojung KIM, Lauren SUAREZ, Ken CARTER, Scott CARMER, Dan BEDNARIK
  • Patent number: 11007222
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 18, 2021
    Assignee: NEXIMMUNE, INC.
    Inventors: Mathias Oelke, Kristi Jones, Sojung Kim, Lauren Suarez, Ken Carter, Scott Carmer, Dan Bednarik, Vineetha Edavana, Emily Lu
  • Publication number: 20200215115
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Application
    Filed: December 9, 2019
    Publication date: July 9, 2020
    Inventors: Mathias OELKE, Kristi JONES, Sojung KIM, Lauren SUAREZ, Ken CARTER, Scott CARMER, Dan BEDNARIK, Vineetha EDAVANA, Emily LU
  • Publication number: 20200188435
    Abstract: The present invention provides an isolated cell composition, which in some embodiments is suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s), which comprises T memory stem (TSCM) cells. In various embodiments, the composition is from about 1% to about 100% T memory stem cells, providing for a robust and durable adoptive therapy, as well as providing for T cell engineering advances.
    Type: Application
    Filed: November 8, 2019
    Publication date: June 18, 2020
    Inventors: Mathias OELKE, Kristi JONES, Sojung KIM, Lauren SUAREZ, Ken CARTER, Scott CARMER, Dan BEDNARIK, Vineetha EDAVANA, Emily LU
  • Publication number: 20190119639
    Abstract: The present invention provides an isolated cell composition suitable for adoptive immunotherapy, as well as methods of manufacturing the cell compositions and methods of treatment with the cell compositions. The composition comprises, in a pharmaceutically acceptable carrier, at least about 106 CD8+ T cells specific for target peptide antigen(s). In various embodiments, the composition is predominately CD8+ T cells, and at least about 20% of T cells in the composition exhibit a central or effector memory phenotype, providing for a robust and durable adoptive therapy from a natural T cell repertoire that has undergone natural selection.
    Type: Application
    Filed: September 20, 2018
    Publication date: April 25, 2019
    Inventors: Mathias OELKE, Kristi JONES, Sojung KIM, Lauren SUAREZ, Ken CARTER, Scott CARMER, Dan BEDNARIK